Our lead drug candidate, 186RNL, is a novel radiotherapeutic with the potential to be a safe, effective and convenient radiation treatment for patients with GBM. Through Convection Enhanced Delivery (CED), 186RNL is “convected” in or adjacent to a tumor, increasing the precision and accuracy of drug delivery while reducing radiation exposure to healthy cells.
As opposed to EBRT, which requires small dose radiation treatment 5 days per week for 5-8 weeks, 186RNL can be administered during a single surgical procedure and a 3-4 day hospital visit.
In our ReSPECT -GBM Phase I Clinical Trial, supported by the U.S. NIH / NCI, we administered up to 15-20x greater dosing than what’s possible with EBRT without significant toxicity.